Astellas Pharma Overview
- Founded
- 1923

- Status
- Public
- Employees
- 15,455

- Stock Symbol
- 4503

- Investments
- 29
- Share Price
- $16.01
- (As of Thursday Closing)
Astellas Pharma General Information
Description
Astellas Pharma Inc is a drug manufacturing company that sells pharmaceutical products across the globe. The vast majority of the company's revenue is derived from Japanese markets, followed by the Americas. Royalty income makes up a small percentage of Astellas' overall sales. Its largest therapeutic area by sales composition is oncology, followed by urology and transplantation. The company uses mergers and acquisitions as part of its long-term growth strategy. Astellas enters into strategic partnerships and licensing agreements to strengthen its commercialization platforms.
Contact Information
- 2-5-1, Nihonbashi-Honcho
- Chuo-ku
- Tokyo, 103-8411
- Japan
Astellas Pharma Stock Performance
(As of Thursday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$16.01 | $15.79 | $14.59 - $18.27 | $29.4B | 1.83B | 5.63M | $0.59 |
Astellas Pharma Financials Summary
In Thousands, USD |
TTM 31-Dec-2021 | FY 2021 31-Mar-2021 | FY 2020 31-Mar-2020 | FY 2019 31-Mar-2019 |
---|---|---|---|---|
EV | 29,966,509 | 29,259,967 | 27,636,821 | 25,970,880 |
Revenue | 11,846,531 | 11,783,609 | 11,963,701 | 11,782,368 |
EBITDA | 2,031,764 | 1,968,163 | 2,854,593 | 2,772,259 |
Net Income | 1,094,278 | 1,137,208 | 1,797,172 | 2,004,679 |
Total Assets | 20,476,445 | 20,610,210 | 21,422,259 | 17,114,508 |
Total Debt | 2,696,109 | 3,147,188 | 4,394,981 | 604,422 |
Astellas Pharma Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
This information is available in the PitchBook Platform. To explore Astellas Pharma‘s full profile, request access.
Request a free trialAstellas Pharma Comparisons
Industry
00000 00
00000000
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialAstellas Pharma Competitors (36)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Intas Pharmaceuticals | Private Equity-Backed | Ahmedabad, India | 00000 | 000.00 | 00000000000 | 000.00 |
000000000 000000 | Corporation | Hyderabad, India | 00000 | 00000 | 000000000 | 00000 |
000 000000 | Corporate Backed or Acquired | Monheim, Germany | 0000 | 000000&0 | ||
000000000 | Corporation | Mumbai, India | 0000 | 000000000 | ||
000000 | Formerly PE-Backed | Bangalore, India | 00000 | 000.00 | 00000000 | 000.00 |
Astellas Pharma Patents
Astellas Pharma Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2020283372-A1 | Method for treating muscular dystrophy by targeting dmpk gene | Pending | 28-May-2019 | 0000000000000 | |
US-20210355464-A1 | Method for treating muscular dystrophy by targeting utrophin gene | Pending | 16-Nov-2018 | 0000000000 | |
AU-2019381460-A1 | Method for treating muscular dystrophy by targeting utrophin gene | Pending | 16-Nov-2018 | 0000000000 | |
EP-3880255-A1 | Method for treating muscular dystrophy by targeting utrophin gene | Pending | 16-Nov-2018 | 00000000000 | |
CA-3119618-A1 | Method for treating muscular dystrophy by targeting utrophin gene | Pending | 16-Nov-2018 | C12N15/113 |
Astellas Pharma Executive Team (26)
Astellas Pharma Board Members (8)
Name | Representing | Role | Since |
---|---|---|---|
000000 000000000 | Astellas Pharma | Board Member | 000 0000 |
00000 00000000 00.0 | Astellas Pharma | Chief Executive Officer & Board Member | 000 0000 |
00000 0000000 | Astellas Pharma | Chief Financial Officer, Finance & Board Member | 000 0000 |
00000 000000000 | Astellas Pharma | Board Member | 000 0000 |
0000000 000000 | Self | Board Member | 000 0000 |
Astellas Pharma Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialAstellas Pharma Investments & Acquisitions (29)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
0000000 00000 | 18-Dec-2020 | 0000000000 | Pharmaceuticals | ||
00000 0000000 | 21-Apr-2020 | 0000000000 | 000.00 | Drug Discovery | 00000 000 |
00000000 0000 | 15-Jan-2020 | 0000000000 | 00.000 | Biotechnology | 00000 000 |
000000 000000 | 26-Dec-2019 | 0000000000 | 00000 | Biotechnology | 00000 000 |
ARCHES Technology | 28-Oct-2019 | Grant | 0000 | Enterprise Systems (Healthcare) |
Astellas Pharma Subsidiaries (11)
Company Name | Industry | Location | Founded |
---|---|---|---|
Xyphos Biosciences | Biotechnology | South San Francisco, CA | 2017 |
0000000 0000000000 | Biotechnology | Cambridge, MA | 0000 |
000000000 00000 | Biotechnology | Seattle, WA | 0000 |
00000 000000000000 | Drug Discovery | Cambridge, United Kingdom | 0000 |
00000000 000000000 | Biotechnology | San Francisco, CA | 0000 |
Astellas Pharma Exits (6)
Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
---|---|---|---|---|---|
000000 000 | 02-Jun-2015 | 00000 00000 00 | 000.00 | Completed |
|
000000 000 | 29-May-2015 | 00000 0000000 | 00000 | Completed |
|
00000 00000000 000 | 01-Oct-2013 | 00000 0000000 | Completed |
|
|
0000000 (000000000 | 22-Jun-2009 | 000000000 00000 00 | 0000 | Completed |
|
FibroGen | 10-Jan-2007 | Later Stage VC | 0000 | Completed |
|